我国多发性硬化诊治现状与进展

Current situation and progress of diagnosis and treatment of multiple sclerosis in China

多发性硬化(multiple sclerosis,MS)是一种好发于中青年患者的中枢神经系统自身免疫性疾病。目前我国MS的诊断多根据2010年Mc Donald诊断标准,但我国视神经脊髓炎发病率较欧美国家高,因此MS与视神经脊髓炎的鉴别诊断十分重要。MS急性期治疗多以大剂量激素冲击为主,由于我国疾病修饰药物缺乏,缓解期治疗多使用免疫抑制剂。我国MS的诊治与欧美发达国家之间还存在一定差距,建立大规模、多中心的MS病例数据库,建立MS患者长期随访机制,提高基层医院MS的早期诊断和治疗水平,以及推进疾病修饰治疗药物进入国内市场,加强新药研发等,都是需要努力的方向。

Multiple sclerosis（MS）is a central nervous system autoimmune disease which mostly involve young patients. Diagnosis of MS in our country is mainly based on 2010 revisions to the Mc Donald criteria. Taken into consideration of the relatively high morbidity of neuromyelitis optica spectrum disorders（NMOSD） in China,the differential diagnosis of MS and NMOSD is important. The main treatment strategy in acute phase is high-dose glucocorticoid,while the main therapy in remission phase is immunosuppressive drugs in our country due to lack of disease modifying medication. The difference between our country and developed countries in Europe and America in the diagnosis and treatment of MS is still exist. Developing large and multi-center MS case database,improving the ability of early diagnosis and treatment of MS in primary hospital,promoting the availability of disease modifying medication on Chinese market,as well as promoting new drug research and development,are all effective ways to improve the situation.